Abstract
Haptoglobin (Hp) polymorphism has recently been demonstrated to be associated with cardiovascular risk and to impact significantly the disease-preventing and therapeutic effects of antioxidant vitamin E in disorders associated with increased oxidative stress, such as diabetes. This suggests that patient population selection based on disease type and Hp polymorphism may dramatically improve the disease-preventing and therapeutic effects of vitamin E administration.
